AstraZeneca
widens cancer push with up to
0 mln
Heptares deal
LONDON, Aug 6 (Reuters) -
AstraZeneca expanded its
push into
cancer immu**therapy on Thursday by striking a
deal potentially worth more than
0 million
with Sosei's biotech unit Heptares, giving it rights to an experimental treatment.
